Mj. Terol et al., EXPRESSION OF THE ADHESION MOLECULE ICAM-1 IN NON-HODGKINS-LYMPHOMA -RELATIONSHIP WITH TUMOR DISSEMINATION AND PROGNOSTIC IMPORTANCE, Journal of clinical oncology, 16(1), 1998, pp. 35-40
Purpose: To study the expression of intercellular adhesion molecule-1
(ICAM-1) by non-Hodgkin's lymphomas and to assess its correlation with
disease extension and prognosis. Patients and Methods: ICAM-1 (CD54-I
OL54) expression was studied in 70 patients (35 male/35 female; median
age, 56 years) with non-Hodgkin's lymphoma from a single institution.
Immunostaining was performed using a streptavidine-biotin alkaline ph
osphatase method and ICAM-1 expression was evaluated in a semiquantita
tive manner. The histologic distribution of the cases was the followin
g: small lymphocytic, five cases; follicular, 14; mantle cell, five; d
iffuse large cell, 41; and T lymphoblastic, five. Forty patients (57%)
were in stage IV, bulky disease was observed in 25 patients (36%), an
d extranodal involvement in 48 patients (69%). Results: ICAM-1 express
ion was negative (-) in 14 patients (20%), weak (+) in 21 (30%), posit
ive (++) in 30 (43%), and strongly positive (+++) in five (7%). No sig
nificant relationship was found between ICAM-1 expression and the lymp
homa histologic subtype. Patients with negative or weak ICAM-1 express
ion had more frequently disseminated (stage IV) disease (74% v 40%; P
= .007), extranodal involvement (86% v 51%; P = .004), and bone marrow
infiltration (57% v 26%; P = .015) than the remainders. Positive ICAM
-1 patients had survival rates significantly better than those in whom
ICAM-1 was negative or weakly expressed [2-year overall survival: 77%
v 50%, respectively; P < .025]. In a multivariate study, ICAM-1 (P =
.005) maintained, along with histologic subtype (P = .001) and the int
ernational prognostic index (IPI) (P = .056), its importance for predi
cting survival. Finally, when the group of aggressive non-Hodgkin's ly
mphoma patients was analyzed, ICAM-1 expression inversely correlated w
ith advanced stage (P = .025), extranodal involvement (P = .01), and b
one marrow infiltration (P = .01), complete response (CR) achievement
(65% v 32%; P = .025), and overall survival (70% v 26% at 2 years; P <
.005). Conclusion: In lymphoma patients, ICAM-1 expression correlates
with lymphoma dissemination and is useful to assess prognosis. (C) 19
98 by American Society of Clinical Oncology.